Jump to content

Fosaprepitant

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 07:30, 2 October 2022 (Add: s2cid. | Use this bot. Report bugs. | Suggested by Whywhenwhohow | #UCB_webform 86/207). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fosaprepitant
Skeletal formula of fosaprepitant
Space-filling model of the fosaprepitant molecule
Clinical data
Trade namesEmend, Ivemend
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa604003
License data
Pregnancy
category
  • AU: B2
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilityn/a
Protein binding>95% (aprepitant)
MetabolismTo aprepitant
Elimination half-life9 to 13 hours (aprepitant)
Identifiers
  • [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H22F7N4O6P
Molar mass614.414 g·mol−1
3D model (JSmol)
  • C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F
  • InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1 ☒N
  • Key:BARDROPHSZEBKC-OITMNORJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication,[3] administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States,[4] and in the European Union in January 2008.[2]

References

  1. ^ "Emend- fosaprepitant dimeglumine injection, powder, lyophilized, for solution". DailyMed. 2 May 2022. Archived from the original on 1 December 2021. Retrieved 27 September 2022.
  2. ^ a b "Ivemend EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 31 December 2021. Retrieved 27 September 2022.
  3. ^ Garnock-Jones KP (September 2016). "Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy". Drugs. 76 (14): 1365–72. doi:10.1007/s40265-016-0627-7. PMID 27510503. S2CID 30018182.
  4. ^ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Archived from the original on 2008-04-09. Retrieved 2008-03-15.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Fosaprepitant&oldid=1113591248"